Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The CHALLENGER Registry

NCT: NCT07197840 · RECRUITING

NCT IDNCT07197840
StatusRECRUITING
Start Date2025-11-20
Completion2028-03-01
SponsorIcahn School of Medicine at Mount Sinai (OTHER)
First posted
Last updated

Brief Summary

The study is a multi-center prospective, single-arm, post-market study evaluating the efficacy and radiologic and functional outcomes associated use of the Numen SILK coils for Middle Meningeal Artery (MMA) embolization following Chronic Subdural Hematoma (cSDH) compared to surgical evacuation or medical management alone. Chronic subdural hematoma is a collection of blood between the dural mater and the brain. It typically develops over time in older adults or people on anticoagulant medication. Blood slowly accumulates over time and often becomes encapsulated by a fibrous membrane over weeks or months, which can lead to the gradual development of symptoms. Middle Meningeal Artery embolization (MMAE) through coiling provides a minimally invasive option for cSDH treatment and prevention of reaccumulation and recurrence.

Frequently Asked Questions

What is The CHALLENGER Registry?

The CHALLENGER Registry is a clinical trial registered under NCT07197840. Current status: RECRUITING.

What is the status of NCT07197840?

The current status of NCT07197840 (The CHALLENGER Registry) is: RECRUITING.

When did The CHALLENGER Registry start?

The CHALLENGER Registry started on 2025-11-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.